EPO Aggressive Dosing May Increase Cardiovascular Risk – NEJM Studies
Executive Summary
Two recently published studies may curtail aggressive elevation of hemoglobin levels with erythropoiesis-stimulating agents in anemia patients
You may also be interested in...
ESA Labeling Should Explain Hemoglobin Target, Advisory Committee Says
Treatment targets for erythropoiesis-stimulating agents in the renal setting need to be accompanied by clinical management information, FDA's Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees says
ESA Labeling Should Explain Hemoglobin Target, Advisory Committee Says
Treatment targets for erythropoiesis-stimulating agents in the renal setting need to be accompanied by clinical management information, FDA's Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees says
Aranesp Trial May Allay EPO Concerns Despite Failing On Primary Endpoint
Results from an Amgen trial showing that anemia therapy Aranesp has a neutral impact on survival in cancer patients receiving chemotherapy could assuage concerns over the safety profile of erythropoiesis-stimulating agents at high doses